Akari Therapeutics ADR (AKTX)

$0.76 -0.02 (-2.64%)
Market Cap 25.73M
Revenue (ttm) 0.00
Net Income (ttm) -19.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.03
Volume 43,417
Avg Vol 55,496
Day's Range N/A - N/A
Shares Out 32.62M
Stochastic %K 57%
Beta 0.27
Analysts Strong Sell
Price Target $4.53

Company Profile

Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads in...

Industry: Biotechnology
Sector: Healthcare
Phone: 929 274 7510
Fax: 929 274 7553
Address:
22 Boston Wharf Road, Floor 7, Boston, United States
jennybaby
jennybaby Sep. 12 at 3:43 PM
$AKTX this “visible” bid is clearly intentional to show a ceiling on a stock whose average daily volume is 1/5th of that. Let’s see if it can get absorbed. It’s been lingering for a couple of days now.
0 · Reply
jennybaby
jennybaby Sep. 11 at 3:10 PM
$AKTX hahaha.
0 · Reply
dan16
dan16 Sep. 10 at 2:14 AM
$AKTX https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-rating-on-akari-therapeutics-stock-at-160-93CH-4231124
0 · Reply
JarvisFlow
JarvisFlow Sep. 9 at 10:30 AM
HC Wainwright & Co. updates rating for Akari Therapeutics ( $AKTX ) to Buy, target set at 1.6.
0 · Reply
jennybaby
jennybaby Sep. 5 at 9:52 PM
$AKTX I was delusional and bought more on that horrific dip. I hope I can at least get out breakeven at this point. If I lose it all, it will hurt me but it won’t kill me. 🤦🏼‍♀️🤦🏼‍♀️🤦🏼‍♀️
0 · Reply
dan16
dan16 Sep. 5 at 8:15 PM
$AKTX all or nothing for me. A conference next week. https://finance.yahoo.com/news/akari-therapeutics-present-h-c-104500042.html
0 · Reply
richeey
richeey Sep. 5 at 7:09 PM
$AKTX only hope is somehow become a meme stock .....with tick cures as our fuel
0 · Reply
dan16
dan16 Sep. 3 at 8:30 PM
$AKTX I hope there is something good said at this thing tomorrow. Or a good press release before the market opens. https://us02web.zoom.us/webinar/register/WN_enKNuhZcR5KGvCEoiJj10g#/registration
1 · Reply
Htsone
Htsone Sep. 3 at 3:09 PM
$AKTX Fellas, it's been good to know ya.
0 · Reply
StockTwitsNinja
StockTwitsNinja Sep. 3 at 2:24 PM
$AKTX Sold half of my holdings yesterday and the rest will go with my grave. Anyone from the old days still around or has everyone already sold?
2 · Reply
Latest News on AKTX
Akari Therapeutics, Plc (AKTX) Discusses At Virtual Investor Closing Bell Series Call (Transcript)

Sep 10, 2025, 1:44 PM EDT - 6 days ago

Akari Therapeutics, Plc (AKTX) Discusses At Virtual Investor Closing Bell Series Call (Transcript)

Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 6:45 AM EDT - 11 days ago

Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series

Sep 3, 2025, 8:30 AM EDT - 13 days ago

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series

Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 9:15 AM EDT - 4 weeks ago

Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

Jul 29, 2025, 9:15 AM EDT - 7 weeks ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

Jul 23, 2025, 8:55 AM EDT - 7 weeks ago

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

Akari Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 2 months ago

Akari Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent

Jun 25, 2025, 9:00 AM EDT - 2 months ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

Jun 18, 2025, 8:50 AM EDT - 3 months ago

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

May 29, 2025, 9:15 AM EDT - 3 months ago

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

May 22, 2025, 9:00 AM EDT - 4 months ago

Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

May 19, 2025, 8:00 AM EDT - 4 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

CRBP QURE

Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025, 8:05 AM EDT - 4 months ago

Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

May 1, 2025, 8:45 AM EDT - 4 months ago

Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

Apr 22, 2025, 9:05 AM EDT - 5 months ago

Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

Mar 20, 2025, 8:35 AM EDT - 6 months ago

Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules

Mar 3, 2025, 9:00 AM EST - 7 months ago

Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules

Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 7 months ago

Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Akari Therapeutics Joins Webull Corporate Connect Service Platform

Feb 3, 2025, 8:00 AM EST - 8 months ago

Akari Therapeutics Joins Webull Corporate Connect Service Platform

Akari Therapeutics Announces Key Leadership Appointments

Dec 18, 2024, 8:51 AM EST - 9 months ago

Akari Therapeutics Announces Key Leadership Appointments

Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

Dec 16, 2024, 9:05 AM EST - 9 months ago

Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

Nov 14, 2024, 4:15 PM EST - 10 months ago

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

Nov 8, 2024, 8:00 AM EST - 11 months ago

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

Aug 19, 2024, 4:15 PM EDT - 1 year ago

Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

May 16, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics

May 1, 2024, 8:01 AM EDT - 1 year ago

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

May 1, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024

Apr 15, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

Apr 1, 2024, 6:30 AM EDT - 1 year ago

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Mar 5, 2024, 8:00 AM EST - 1 year ago

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing

Jan 2, 2024, 8:00 AM EST - 1 year ago

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing

Akari Therapeutics to Present at Biotech Showcase 2024

Dec 14, 2023, 8:00 AM EST - 1 year ago

Akari Therapeutics to Present at Biotech Showcase 2024

Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D.

Dec 1, 2023, 8:00 AM EST - 1 year ago

Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D.

Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Nov 16, 2023, 8:00 AM EST - 1 year ago

Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Nov 6, 2023, 8:00 AM EST - 2 years ago

Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

Sep 29, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

Akari Therapeutics to Present at Emerging Growth Conference

Sep 27, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics to Present at Emerging Growth Conference

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit

Sep 21, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit

Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials

Aug 18, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials

Akari Therapeutics, Plc Announces ADS Ratio Change

Aug 15, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics, Plc Announces ADS Ratio Change

Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs

Aug 2, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs

Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation

Jul 27, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation

Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer

Jul 19, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer

Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA

Jul 13, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA

Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy

Jul 11, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy

Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation

Jul 6, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation

jennybaby
jennybaby Sep. 12 at 3:43 PM
$AKTX this “visible” bid is clearly intentional to show a ceiling on a stock whose average daily volume is 1/5th of that. Let’s see if it can get absorbed. It’s been lingering for a couple of days now.
0 · Reply
jennybaby
jennybaby Sep. 11 at 3:10 PM
$AKTX hahaha.
0 · Reply
dan16
dan16 Sep. 10 at 2:14 AM
$AKTX https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-rating-on-akari-therapeutics-stock-at-160-93CH-4231124
0 · Reply
JarvisFlow
JarvisFlow Sep. 9 at 10:30 AM
HC Wainwright & Co. updates rating for Akari Therapeutics ( $AKTX ) to Buy, target set at 1.6.
0 · Reply
jennybaby
jennybaby Sep. 5 at 9:52 PM
$AKTX I was delusional and bought more on that horrific dip. I hope I can at least get out breakeven at this point. If I lose it all, it will hurt me but it won’t kill me. 🤦🏼‍♀️🤦🏼‍♀️🤦🏼‍♀️
0 · Reply
dan16
dan16 Sep. 5 at 8:15 PM
$AKTX all or nothing for me. A conference next week. https://finance.yahoo.com/news/akari-therapeutics-present-h-c-104500042.html
0 · Reply
richeey
richeey Sep. 5 at 7:09 PM
$AKTX only hope is somehow become a meme stock .....with tick cures as our fuel
0 · Reply
dan16
dan16 Sep. 3 at 8:30 PM
$AKTX I hope there is something good said at this thing tomorrow. Or a good press release before the market opens. https://us02web.zoom.us/webinar/register/WN_enKNuhZcR5KGvCEoiJj10g#/registration
1 · Reply
Htsone
Htsone Sep. 3 at 3:09 PM
$AKTX Fellas, it's been good to know ya.
0 · Reply
StockTwitsNinja
StockTwitsNinja Sep. 3 at 2:24 PM
$AKTX Sold half of my holdings yesterday and the rest will go with my grave. Anyone from the old days still around or has everyone already sold?
2 · Reply
jennybaby
jennybaby Sep. 2 at 2:55 PM
$AKTX if this isn’t textbook capitulation, I don’t know what is. 🤦🏼‍♀️🤦🏼‍♀️🤦🏼‍♀️🤦🏼‍♀️
1 · Reply
richardxkxkTwits
richardxkxkTwits Sep. 2 at 2:20 PM
$AKTX white lion dumping shares
1 · Reply
Jtlo
Jtlo Aug. 31 at 9:34 PM
$AKTX how much cash on hands
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Aug. 29 at 11:00 PM
$AKTX CEO purchased 21,000 shares at $0.93 for a total of $19,540. Gaslightwala Abizer now owns 298,574 shares. https://ceo-buys.com
0 · Reply
MTN
MTN Aug. 28 at 7:48 PM
$AKTX insiders have spent 10s of millions on this, wonder if they are finally throwing in the towel. I can't even imagine wasting that much money to not even have one drug pass P3. They didnt even try.
3 · Reply
Stetters9
Stetters9 Aug. 28 at 6:40 PM
$AKTX
0 · Reply
StockTwitsNinja
StockTwitsNinja Aug. 28 at 4:43 PM
$AKTX
0 · Reply
Bart69
Bart69 Aug. 28 at 12:28 PM
$AKTX Reloading what I sold. Adding. This looks familiar.
0 · Reply
Pennybags01
Pennybags01 Aug. 25 at 8:30 PM
$AKTX everything that ever came to the finish line got shelved and then shareholders would get diluted more. Nothing of value ever comes here. When death?
1 · Reply
HeroBullDog
HeroBullDog Aug. 25 at 3:21 PM
$AKTX i noticed on my watchlist that this is at an all time low, every time i notice a stock like this it gets a run soon after especially if i didn't buy lol so hopefully for y'all holding it gets a run
1 · Reply
StockTwitsNinja
StockTwitsNinja Aug. 21 at 2:41 PM
$AKTX It’s extremely frustrating and disheartening to see so little visible effort from leadership in defending the stock. With no funds in play and the stock sliding day after day, it feels like nothing is being done. The countdown to the next RS has already begun.
0 · Reply
718Pigeon
718Pigeon Aug. 15 at 4:31 AM
$AKTX are they still trying to find miracles out of Ticks blood? 🩸 🗣️
0 · Reply